Tumour growth kinetics and the behaviour of cancer cells
How fast tumours grow, why they are found late, and which normal growth brakes cancer cells lose.
Key facts
- Doubling time, the time a tumour takes to double in size, ranges from days (some lymphomas and childhood tumours) to months or years (many carcinomas).
- About 30 doublings turn one cell into a tumour of about 1 cm (around 10⁹ cells), the size at which it is usually found; only about 10 more doublings reach a lethal mass.
- Growth is Gompertzian: fast while small, then slower as the tumour outgrows its blood supply and loses more cells.
- Normal cells stop dividing when they touch each other (contact inhibition) and need to be attached to divide (anchorage dependence); cancer cells lose both, pile up in layers and grow even in soft agar.
- Chemotherapy kills a constant fraction of cells with each cycle (log kill), and dividing cells are the most sensitive.
Small or large tumour?
| Feature | Small (early or left after surgery) | Large (bulky, late) |
|---|---|---|
| Growth fraction | High: most cells are dividing | Low: many cells resting or dying |
| Doubling time | Short | Longer (Gompertzian slowing) |
| Blood supply and oxygen | Good | Poor centre, hypoxia and necrosis |
| Sensitivity to chemotherapy | High | Lower |
| Resistant clones | Few | More likely to be present already |
In detail
- The growth fraction is the share of tumour cells that are dividing; it is high in small tumours and falls as they grow.
- Repeated cycles, combinations of drugs and adjuvant treatment after surgery aim at a small tumour burden, when the growth fraction is high and fewer resistant cells exist.
- Oncofetal antigens are fetal proteins re-expressed by tumours: α-fetoprotein (hepatocellular carcinoma, germ-cell tumours) and carcinoembryonic antigen (colorectal cancer).
- Tissue polypeptide antigen and related markers (TPS, CYFRA 21-1) are cytokeratin fragments released by proliferating epithelial tumour cells; they reflect proliferation but are not specific for any tumour.
- Also called
- Doubling time and Gompertzian growth, Contact inhibition and anchorage dependence
Clinical notes
- Because a tumour has gone through most of its doublings before it can be felt or seen, screening aims to find it earlier.
- Tumour markers are best used to follow treatment and recurrence, not to screen healthy people.
Common traps
- A tumour found at 1 cm has only just started: it has already gone through about 30 of the roughly 40 doublings to a lethal size, often years of silent growth.
- Each chemotherapy cycle removes a fixed number of cells: it removes a fixed fraction (log kill), so killing 99 % of 10¹¹ cells still leaves 10⁹, a tumour of detectable size.
- Large tumours grow fastest because they have the most cells: their growth fraction is lower and their doubling time longer; small tumours grow proportionally faster.
- A raised tumour marker in a healthy person means cancer: markers lack the sensitivity and specificity for screening; they are mainly used to follow a known tumour.
Test yourself
Think of the answer, then tap the question to see it.
Why is a 1 cm tumour already «old»?
It has gone through about 30 of the roughly 40 doublings to a lethal size, so most of its life is already behind it.
What does «log kill» mean in chemotherapy?
Each cycle kills a constant fraction of tumour cells, not a constant number, so repeated cycles are needed.
A child with Burkitt lymphoma, which has a very short doubling time, starts chemotherapy and two days later has high potassium, phosphate and uric acid. Why?
A very high growth fraction makes the tumour exquisitely sensitive: huge numbers of cells die at once and release their contents (tumour lysis syndrome).
After a breast cancer is completely removed, chemotherapy is given although no tumour can be seen. Why?
Any micrometastases are small, with a high growth fraction and few resistant cells, so log kill is most likely to eradicate them now.
Connections
Educational information, not medical advice. For any symptom, see a health professional.
Sources: What Is Cancer? (National Cancer Institute (NCI), 2026); Tumor Markers (National Cancer Institute (NCI), 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
